Effects of Equol Supplement on Bone and Cardiovascular Parameters in Middle-Aged Japanese Women: A Prospective Observational Study
Objective: To examine changes in the bone and cardiovascular parameters and tolerability in middle-aged Japanese women taking equol supplement for a year. Design: This was a prospective observational study. Subjects and Setting: Participants were 74 women receiving outpatient care at Hamasite Medica...
Gespeichert in:
| Veröffentlicht in: | Journal of integrative and complementary medicine (Print) 2018-07, Vol.24 (7), p.71-708 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 708 |
|---|---|
| container_issue | 7 |
| container_start_page | 71 |
| container_title | Journal of integrative and complementary medicine (Print) |
| container_volume | 24 |
| creator | Yoshikata, Remi Myint, Khin Zay Yar Ohta, Hiroaki |
| description | Objective:
To examine changes in the bone and cardiovascular parameters and tolerability in middle-aged Japanese women taking equol supplement for a year.
Design:
This was a prospective observational study.
Subjects and Setting:
Participants were 74 women receiving outpatient care at Hamasite Medical Clinic, Minato-ku, Tokyo, from 2013 to 2015.
Interventions:
Participants received per oral equol-containing supplement, 10 mg/day.
Outcome measures:
The primary outcome measures were percent changes in bone and cardiovascular parameters after 1 year supplementation with equol. The secondary measures included factors affecting the parameter changes and adverse effects associated with equol use for a year.
Results:
Reduction in arterial stiffness was observed after 12 months of equol supplement (1402.3 cm/s vs.1367.3 cm/s,
p
|
| doi_str_mv | 10.1089/acm.2018.0050 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6065522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A573095742</galeid><sourcerecordid>A573095742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c695t-c33a4c4ced6be6a5511c4a141890e99941ddbde8aa553866b15cdff197e14a103</originalsourceid><addsrcrecordid>eNqFkt-L1DAQx4so3g999FUCguhD16RN2uYehHVZT2VlD1R8DGky3c2RNr2kXe5e_ctNufO8lQXJQ8LMZ77D5DtJ8oLgGcEVfydVO8swqWYYM_woOSaMlWlZ4upxfOOSpYzl7Cg5CeESY0wpz54mRxkvs4xRfpz8WjYNqCEg16Dl1egs-jb2vYUWugG5Dn1wHSDZabSQXhu3k0GNVnp0Ib1sYQAfkOnQV6O1hXS-AY2-yF52EAD9dFHkDM3RhXehj03MDtC6DuB3cjCuk7HXMOqbZ8mTRtoAz-_u0-THx-X3xad0tT7_vJivUlVwNqQqzyVVVIEuaigkY4QoKgklFcfAOadE61pDJWMqr4qiJkzppiG8BBI5nJ8m7291-7FuQas4oZdW9N600t8IJ43Yz3RmKzZuJwpcMJZlUeDNnYB3VyOEQbQmKLA2zuvGIDKc04wTVuURffUPeulGH0eeqBLTvCwI_UttpAVhusbFvmoSFXNW5pizkk5tZweoeDS0RkV_GhPjewVv9woiM8D1sJFjCKI6X-2z6SFWOWthAyIasFjv868f8FuQdtgGZ8fJ0HBQWEX3g4fm_qMJFtPmijipmDZXTJsb-ZcP3bmn_6xqBPJbYArLrrMGavDDf2R_A79E9_g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2070437614</pqid></control><display><type>article</type><title>Effects of Equol Supplement on Bone and Cardiovascular Parameters in Middle-Aged Japanese Women: A Prospective Observational Study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Yoshikata, Remi ; Myint, Khin Zay Yar ; Ohta, Hiroaki</creator><creatorcontrib>Yoshikata, Remi ; Myint, Khin Zay Yar ; Ohta, Hiroaki</creatorcontrib><description>Objective:
To examine changes in the bone and cardiovascular parameters and tolerability in middle-aged Japanese women taking equol supplement for a year.
Design:
This was a prospective observational study.
Subjects and Setting:
Participants were 74 women receiving outpatient care at Hamasite Medical Clinic, Minato-ku, Tokyo, from 2013 to 2015.
Interventions:
Participants received per oral equol-containing supplement, 10 mg/day.
Outcome measures:
The primary outcome measures were percent changes in bone and cardiovascular parameters after 1 year supplementation with equol. The secondary measures included factors affecting the parameter changes and adverse effects associated with equol use for a year.
Results:
Reduction in arterial stiffness was observed after 12 months of equol supplement (1402.3 cm/s vs.1367.3 cm/s,
p
< 0.001). Significant reductions in respective parameters were observed in women with moderate and high risk for arteriosclerosis (median [95% confidence interval]: −3.2% [−5.79 to −0.74]; −12.65% [−18.52 to −4.28]; respectively); hypertriglyceridemia −45.53% [−70.24 to −5.58]; bone resorption risk (−15.15% [−23.71 to 1.56]; and bone fracture risk −26.68% [−76.43 to −5.99]. All 15 women with high baseline parathyroid hormone levels had achieved a median of 50% [−54.11 to −31.69] reduction from their baseline values. These associations were further confirmed in the results of multiple linear regression analysis. There were no reported adverse events or abnormal findings in the blood chemistry, Pap smear, mammography, and transvaginal ultrasound during periodic follow-ups.
Conclusion:
One year equol supplement was tolerable and induced improvement of certain bone and cardiovascular parameters, especially in higher risk groups. Further controlled studies are needed to explore long-term equol use for wellbeing of middle-aged women.</description><identifier>ISSN: 1075-5535</identifier><identifier>ISSN: 1326-3390</identifier><identifier>ISSN: 2768-3605</identifier><identifier>EISSN: 1557-7708</identifier><identifier>EISSN: 2768-3613</identifier><identifier>DOI: 10.1089/acm.2018.0050</identifier><identifier>PMID: 29722549</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Arteriosclerosis ; Bioflavonoids ; Bone diseases ; Bone resorption ; Cardiovascular diseases ; Care and treatment ; Collagen Type I - urine ; Dietary supplements ; Equol - administration & dosage ; Equol - pharmacology ; Equol - therapeutic use ; Female ; Flavones ; Flavonoids ; Health aspects ; Health risks ; Humans ; Hypertriglyceridemia ; Lipids - blood ; Mammography ; Middle age ; Middle Aged ; Middle aged women ; Observational studies ; Original ; Original Articles ; Parathyroid ; Parathyroid hormone ; Parathyroid Hormone - blood ; Peptides - urine ; Prospective Studies ; Regression analysis ; Risk groups ; Smear ; Treatment Outcome ; Ultrasound ; Vascular Stiffness - drug effects</subject><ispartof>Journal of integrative and complementary medicine (Print), 2018-07, Vol.24 (7), p.71-708</ispartof><rights>Remi Yoshikata et al.</rights><rights>COPYRIGHT 2018 Australian Traditional-Medicine Society</rights><rights>COPYRIGHT 2018 Australian Traditional-Medicine Society</rights><rights>(©) © Remi Yoshikata et al.</rights><rights>Remi Yoshikata et al., 2018; Published by Mary Ann Liebert, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c695t-c33a4c4ced6be6a5511c4a141890e99941ddbde8aa553866b15cdff197e14a103</citedby><cites>FETCH-LOGICAL-c695t-c33a4c4ced6be6a5511c4a141890e99941ddbde8aa553866b15cdff197e14a103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29722549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshikata, Remi</creatorcontrib><creatorcontrib>Myint, Khin Zay Yar</creatorcontrib><creatorcontrib>Ohta, Hiroaki</creatorcontrib><title>Effects of Equol Supplement on Bone and Cardiovascular Parameters in Middle-Aged Japanese Women: A Prospective Observational Study</title><title>Journal of integrative and complementary medicine (Print)</title><addtitle>J Altern Complement Med</addtitle><description>Objective:
To examine changes in the bone and cardiovascular parameters and tolerability in middle-aged Japanese women taking equol supplement for a year.
Design:
This was a prospective observational study.
Subjects and Setting:
Participants were 74 women receiving outpatient care at Hamasite Medical Clinic, Minato-ku, Tokyo, from 2013 to 2015.
Interventions:
Participants received per oral equol-containing supplement, 10 mg/day.
Outcome measures:
The primary outcome measures were percent changes in bone and cardiovascular parameters after 1 year supplementation with equol. The secondary measures included factors affecting the parameter changes and adverse effects associated with equol use for a year.
Results:
Reduction in arterial stiffness was observed after 12 months of equol supplement (1402.3 cm/s vs.1367.3 cm/s,
p
< 0.001). Significant reductions in respective parameters were observed in women with moderate and high risk for arteriosclerosis (median [95% confidence interval]: −3.2% [−5.79 to −0.74]; −12.65% [−18.52 to −4.28]; respectively); hypertriglyceridemia −45.53% [−70.24 to −5.58]; bone resorption risk (−15.15% [−23.71 to 1.56]; and bone fracture risk −26.68% [−76.43 to −5.99]. All 15 women with high baseline parathyroid hormone levels had achieved a median of 50% [−54.11 to −31.69] reduction from their baseline values. These associations were further confirmed in the results of multiple linear regression analysis. There were no reported adverse events or abnormal findings in the blood chemistry, Pap smear, mammography, and transvaginal ultrasound during periodic follow-ups.
Conclusion:
One year equol supplement was tolerable and induced improvement of certain bone and cardiovascular parameters, especially in higher risk groups. Further controlled studies are needed to explore long-term equol use for wellbeing of middle-aged women.</description><subject>Arteriosclerosis</subject><subject>Bioflavonoids</subject><subject>Bone diseases</subject><subject>Bone resorption</subject><subject>Cardiovascular diseases</subject><subject>Care and treatment</subject><subject>Collagen Type I - urine</subject><subject>Dietary supplements</subject><subject>Equol - administration & dosage</subject><subject>Equol - pharmacology</subject><subject>Equol - therapeutic use</subject><subject>Female</subject><subject>Flavones</subject><subject>Flavonoids</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>Humans</subject><subject>Hypertriglyceridemia</subject><subject>Lipids - blood</subject><subject>Mammography</subject><subject>Middle age</subject><subject>Middle Aged</subject><subject>Middle aged women</subject><subject>Observational studies</subject><subject>Original</subject><subject>Original Articles</subject><subject>Parathyroid</subject><subject>Parathyroid hormone</subject><subject>Parathyroid Hormone - blood</subject><subject>Peptides - urine</subject><subject>Prospective Studies</subject><subject>Regression analysis</subject><subject>Risk groups</subject><subject>Smear</subject><subject>Treatment Outcome</subject><subject>Ultrasound</subject><subject>Vascular Stiffness - drug effects</subject><issn>1075-5535</issn><issn>1326-3390</issn><issn>2768-3605</issn><issn>1557-7708</issn><issn>2768-3613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>1-M</sourceid><sourceid>EIF</sourceid><recordid>eNqFkt-L1DAQx4so3g999FUCguhD16RN2uYehHVZT2VlD1R8DGky3c2RNr2kXe5e_ctNufO8lQXJQ8LMZ77D5DtJ8oLgGcEVfydVO8swqWYYM_woOSaMlWlZ4upxfOOSpYzl7Cg5CeESY0wpz54mRxkvs4xRfpz8WjYNqCEg16Dl1egs-jb2vYUWugG5Dn1wHSDZabSQXhu3k0GNVnp0Ib1sYQAfkOnQV6O1hXS-AY2-yF52EAD9dFHkDM3RhXehj03MDtC6DuB3cjCuk7HXMOqbZ8mTRtoAz-_u0-THx-X3xad0tT7_vJivUlVwNqQqzyVVVIEuaigkY4QoKgklFcfAOadE61pDJWMqr4qiJkzppiG8BBI5nJ8m7291-7FuQas4oZdW9N600t8IJ43Yz3RmKzZuJwpcMJZlUeDNnYB3VyOEQbQmKLA2zuvGIDKc04wTVuURffUPeulGH0eeqBLTvCwI_UttpAVhusbFvmoSFXNW5pizkk5tZweoeDS0RkV_GhPjewVv9woiM8D1sJFjCKI6X-2z6SFWOWthAyIasFjv868f8FuQdtgGZ8fJ0HBQWEX3g4fm_qMJFtPmijipmDZXTJsb-ZcP3bmn_6xqBPJbYArLrrMGavDDf2R_A79E9_g</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Yoshikata, Remi</creator><creator>Myint, Khin Zay Yar</creator><creator>Ohta, Hiroaki</creator><general>Mary Ann Liebert, Inc</general><general>Australian Traditional-Medicine Society</general><scope>1-M</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8GL</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180701</creationdate><title>Effects of Equol Supplement on Bone and Cardiovascular Parameters in Middle-Aged Japanese Women: A Prospective Observational Study</title><author>Yoshikata, Remi ; Myint, Khin Zay Yar ; Ohta, Hiroaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c695t-c33a4c4ced6be6a5511c4a141890e99941ddbde8aa553866b15cdff197e14a103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Arteriosclerosis</topic><topic>Bioflavonoids</topic><topic>Bone diseases</topic><topic>Bone resorption</topic><topic>Cardiovascular diseases</topic><topic>Care and treatment</topic><topic>Collagen Type I - urine</topic><topic>Dietary supplements</topic><topic>Equol - administration & dosage</topic><topic>Equol - pharmacology</topic><topic>Equol - therapeutic use</topic><topic>Female</topic><topic>Flavones</topic><topic>Flavonoids</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>Humans</topic><topic>Hypertriglyceridemia</topic><topic>Lipids - blood</topic><topic>Mammography</topic><topic>Middle age</topic><topic>Middle Aged</topic><topic>Middle aged women</topic><topic>Observational studies</topic><topic>Original</topic><topic>Original Articles</topic><topic>Parathyroid</topic><topic>Parathyroid hormone</topic><topic>Parathyroid Hormone - blood</topic><topic>Peptides - urine</topic><topic>Prospective Studies</topic><topic>Regression analysis</topic><topic>Risk groups</topic><topic>Smear</topic><topic>Treatment Outcome</topic><topic>Ultrasound</topic><topic>Vascular Stiffness - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshikata, Remi</creatorcontrib><creatorcontrib>Myint, Khin Zay Yar</creatorcontrib><creatorcontrib>Ohta, Hiroaki</creatorcontrib><collection>Mary Ann Liebert Online - Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: High School</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of integrative and complementary medicine (Print)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshikata, Remi</au><au>Myint, Khin Zay Yar</au><au>Ohta, Hiroaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Equol Supplement on Bone and Cardiovascular Parameters in Middle-Aged Japanese Women: A Prospective Observational Study</atitle><jtitle>Journal of integrative and complementary medicine (Print)</jtitle><addtitle>J Altern Complement Med</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>24</volume><issue>7</issue><spage>71</spage><epage>708</epage><pages>71-708</pages><issn>1075-5535</issn><issn>1326-3390</issn><issn>2768-3605</issn><eissn>1557-7708</eissn><eissn>2768-3613</eissn><abstract>Objective:
To examine changes in the bone and cardiovascular parameters and tolerability in middle-aged Japanese women taking equol supplement for a year.
Design:
This was a prospective observational study.
Subjects and Setting:
Participants were 74 women receiving outpatient care at Hamasite Medical Clinic, Minato-ku, Tokyo, from 2013 to 2015.
Interventions:
Participants received per oral equol-containing supplement, 10 mg/day.
Outcome measures:
The primary outcome measures were percent changes in bone and cardiovascular parameters after 1 year supplementation with equol. The secondary measures included factors affecting the parameter changes and adverse effects associated with equol use for a year.
Results:
Reduction in arterial stiffness was observed after 12 months of equol supplement (1402.3 cm/s vs.1367.3 cm/s,
p
< 0.001). Significant reductions in respective parameters were observed in women with moderate and high risk for arteriosclerosis (median [95% confidence interval]: −3.2% [−5.79 to −0.74]; −12.65% [−18.52 to −4.28]; respectively); hypertriglyceridemia −45.53% [−70.24 to −5.58]; bone resorption risk (−15.15% [−23.71 to 1.56]; and bone fracture risk −26.68% [−76.43 to −5.99]. All 15 women with high baseline parathyroid hormone levels had achieved a median of 50% [−54.11 to −31.69] reduction from their baseline values. These associations were further confirmed in the results of multiple linear regression analysis. There were no reported adverse events or abnormal findings in the blood chemistry, Pap smear, mammography, and transvaginal ultrasound during periodic follow-ups.
Conclusion:
One year equol supplement was tolerable and induced improvement of certain bone and cardiovascular parameters, especially in higher risk groups. Further controlled studies are needed to explore long-term equol use for wellbeing of middle-aged women.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>29722549</pmid><doi>10.1089/acm.2018.0050</doi><tpages>638</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1075-5535 |
| ispartof | Journal of integrative and complementary medicine (Print), 2018-07, Vol.24 (7), p.71-708 |
| issn | 1075-5535 1326-3390 2768-3605 1557-7708 2768-3613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6065522 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Arteriosclerosis Bioflavonoids Bone diseases Bone resorption Cardiovascular diseases Care and treatment Collagen Type I - urine Dietary supplements Equol - administration & dosage Equol - pharmacology Equol - therapeutic use Female Flavones Flavonoids Health aspects Health risks Humans Hypertriglyceridemia Lipids - blood Mammography Middle age Middle Aged Middle aged women Observational studies Original Original Articles Parathyroid Parathyroid hormone Parathyroid Hormone - blood Peptides - urine Prospective Studies Regression analysis Risk groups Smear Treatment Outcome Ultrasound Vascular Stiffness - drug effects |
| title | Effects of Equol Supplement on Bone and Cardiovascular Parameters in Middle-Aged Japanese Women: A Prospective Observational Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T14%3A28%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Equol%20Supplement%20on%20Bone%20and%20Cardiovascular%20Parameters%20in%20Middle-Aged%20Japanese%20Women:%20A%20Prospective%20Observational%20Study&rft.jtitle=Journal%20of%20integrative%20and%20complementary%20medicine%20(Print)&rft.au=Yoshikata,%20Remi&rft.date=2018-07-01&rft.volume=24&rft.issue=7&rft.spage=71&rft.epage=708&rft.pages=71-708&rft.issn=1075-5535&rft.eissn=1557-7708&rft_id=info:doi/10.1089/acm.2018.0050&rft_dat=%3Cgale_pubme%3EA573095742%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2070437614&rft_id=info:pmid/29722549&rft_galeid=A573095742&rfr_iscdi=true |